Gene expression profiling and identification of novel prognostic marker genes in neuroblastoma

✍ Scribed by Junko Takita; Masami Ishii; Shuichi Tsutsumi; Yukichi Tanaka; Keisuke Kato; Yasunori Toyoda; Ryoji Hanada; Keiko Yamamoto; Yasuhide Hayashi; Hiroyuki Aburatani

• Publisher: John Wiley and Sons
• Year: 2004
• Tongue: English
• Weight: 796 KB
• Volume: 40
• Category: Article
• ISSN: 1045-2257
• DOI: 10.1002/gcc.20021

✦ Synopsis

Abstract

To investigate the various genetic characteristics of and differences between early‐ and advanced‐stage neuroblastoma (NB) and to identify candidate genes involved in NB progression, we performed DNA microarray analysis on 20 primary tumors. Two‐way clustering analysis based on the expression pattern of approximately 500 of 1,700 genes revealed genetic subgroups in these NB tumors. Although 9 of the 13 early‐stage tumors (69%) and 4 of the 6 advanced‐stage tumors (67%) were classified as being in the same cluster, the remaining tumors showed different expression profiles. This indicates that both the early‐ and advanced‐stage tumors were heterogeneous. Based on the microarray data, we identified the BIRC, CDKN2D, and SMARCD3 genes as those that are predominantly expressed in either the early or the advanced stage of NB. These genes have been reported to be associated with apoptosis, cell cycles, and the transcriptional activator, respectively. To better assess the prognostic value of the expression of these genes in NB, real‐time polymerase chain reaction was carried out on 50 primary tumors. The expression of both the BIRC3 and CDKN2D genes was significantly higher in the early‐stage group than in the advanced‐stage group (P = 0.002 and 0.003, respectively), whereas the expression of the SMARCD3 gene was significantly reduced in the early‐stage group (P = 0.02). Therefore, the BIRC, CDKN2D, and SMARCD3 genes are possible candidates for being novel prognostic markers for NB. © 2004 Wiley‐Liss, Inc.